Novo Splashes Out Again To Solve Semaglutide Supply Problem

 
• By Kevin Grogan

Novo Nordisk is buying three manufacturing facilities for $11bn from Catalent, which has just been acquired by the former's main shareholder Novo Holdings, in its latest bid to meet surging demand for its semaglutide-based diabetes and obesity drugs.

Novo Nordisk Kalundborg
Kalundborg, the Danish drugmaker's largest plant • Source: Novo Nordisk

More from Manufacturing

More from Business